Total Payments
$120,151
2024 Payments
$41,168
Companies
19
Transactions
122
Medicare Patients
1,182
Medicare Billing
$111,973
Payment Breakdown by Category
Consulting$58,736 (48.9%)
Research$27,864 (23.2%)
Other$19,250 (16.0%)
Travel$10,431 (8.7%)
Food & Beverage$3,843 (3.2%)
Education$26.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $58,736 | 27 | 48.9% |
| Unspecified | $27,864 | 9 | 23.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,900 | 3 | 15.7% |
| Travel and Lodging | $10,431 | 8 | 8.7% |
| Food and Beverage | $3,843 | 72 | 3.2% |
| Grant | $350.00 | 1 | 0.3% |
| Education | $26.92 | 2 | 0.0% |
Payments by Type
General
$92,287
113 transactions
Research
$27,864
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $26,797 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $25,170 | 33 | $0 (2024) |
| PFIZER INC. | $19,793 | 14 | $0 (2024) |
| Lilly USA, LLC | $10,212 | 4 | $0 (2023) |
| Merck Sharp & Dohme LLC | $9,939 | 7 | $0 (2024) |
| Daiichi Sankyo Inc. | $5,842 | 6 | $0 (2023) |
| Novartis Pharma AG | $5,171 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $4,637 | 3 | $0 (2023) |
| Seagen Inc. | $3,575 | 2 | $0 (2022) |
| AstraZeneca UK Limited | $2,593 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,168 | 21 | Novartis Pharmaceuticals Corporation ($15,487) |
| 2023 | $22,973 | 31 | Novartis Pharmaceuticals Corporation ($5,203) |
| 2022 | $28,447 | 18 | PFIZER INC. ($10,366) |
| 2021 | $12,833 | 13 | Novartis Pharmaceuticals Corporation ($3,930) |
| 2019 | $6,080 | 4 | Eli Lilly and Company ($5,939) |
| 2018 | $7,659 | 13 | Eli Lilly and Company ($7,115) |
| 2017 | $989.74 | 22 | Eli Lilly and Company ($386.74) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $40.08 | General |
| 12/10/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $41.55 | General |
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $226.49 | General |
| 10/31/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $419.92 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,750.00 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $501.96 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $7.65 | General |
| 10/17/2024 | Eli Lilly and Company | VERZENIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,840.00 | General |
| 07/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | — | Cash or cash equivalent | $222.81 | Research |
| Study: CLEE011O12301C • Category: Oncology | ||||||
| 05/31/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 05/16/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $106.13 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $8,609.90 | General |
| 03/14/2024 | Genentech USA, Inc. | — | Food and Beverage | Cash or cash equivalent | $208.72 | General |
| 03/14/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $86.43 | General |
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 02/13/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| 02/06/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | — | Cash or cash equivalent | $6,543.22 | Research |
| Study: CLEE011O12301C • Category: Oncology | ||||||
| 01/24/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $111.12 | General |
| Category: Oncology | ||||||
| 01/23/2024 | Novartis Pharma AG | KISQALI (Drug), KISQALI | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $103.46 | General |
| 12/06/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| Category: Oncology | ||||||
| 12/06/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONC | ||||||
| 12/06/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $115.40 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $13,414 | 3 |
| CLEE011O12301C | Novartis Pharmaceuticals Corporation | $7,431 | 3 |
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $2,893 | 1 |
| KISQALI Study Related Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $2,097 | 1 |
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $2,029 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 181 | 235 | $80,722 | $21,489 |
| 2022 | 4 | 128 | 183 | $63,337 | $18,543 |
| 2021 | 7 | 315 | 397 | $68,098 | $25,301 |
| 2020 | 8 | 558 | 842 | $122,908 | $46,640 |
Total Patients
1,182
Total Services
1,657
Medicare Billing
$111,973
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 53 | $20,301 | $5,984 | 29.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 33 | $12,533 | $3,797 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 41 | $12,699 | $3,127 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $8,037 | $2,617 | 32.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $6,372 | $1,890 | 29.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 32 | $8,540 | $1,644 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 27 | 31 | $8,140 | $1,413 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 13 | $4,100 | $1,018 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 52 | $19,396 | $6,212 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 21 | 33 | $12,309 | $3,812 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $6,615 | $2,291 | 34.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $6,174 | $2,136 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 21 | $6,363 | $1,680 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 26 | $6,760 | $1,331 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 22 | $5,720 | $1,081 | 18.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 68 | 117 | $28,157 | $11,821 | 42.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 125 | 130 | $13,714 | $4,134 | 30.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 57 | 63 | $10,482 | $3,563 | 34.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $6,748 | $2,522 | 37.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 24 | $3,452 | $1,282 | 37.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 15 | $3,145 | $1,207 | 38.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 19 | 31 | $2,400 | $772.54 | 32.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 271 | 381 | $37,719 | $13,297 | 35.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 64 | 147 | $31,605 | $12,570 | 39.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 85 | 138 | $20,976 | $7,881 | 37.6% |
About Dr. Stephanie Graff, M.D
Dr. Stephanie Graff, M.D is a Hematology & Oncology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437187747.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephanie Graff, M.D has received a total of $120,151 in payments from pharmaceutical and medical device companies, with $41,168 received in 2024. These payments were reported across 122 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($58,736).
As a Medicare-enrolled provider, Graff has provided services to 1,182 Medicare beneficiaries, totaling 1,657 services with total Medicare billing of $111,973. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Kansas City, MO
- Active Since 06/28/2006
- Last Updated 03/18/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437187747
Products in Payments
- KISQALI (Drug) $21,514
- IBRANCE (Drug) $5,063
- Trodelvy (Drug) $4,625
- TUKYSA (Drug) $3,575
- VERZENIO (Drug) $2,400
- Orserdu (Drug) $2,220
- Enhertu (Drug) $1,429
- Phesgo (Biological) $990.00
- FOUNDATIONONE (Device) $257.53
- Herceptin (Biological) $139.49
- Perjeta (Biological) $66.13
- ZEJULA (Drug) $33.10
- Truqap (Drug) $30.00
- ELIQUIS (Drug) $23.01
- KEYTRUDA (Biological) $17.08
- EMEND (Drug) $16.32
- Stivarga (Drug) $15.13
- Nerlynx (Drug) $15.00
- TASIGNA (Drug) $10.39
- AFINITOR (Drug) $4.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Kansas City
Dr. Suman Kambhampati, Md, MD
Hematology & Oncology — Payments: $281,918
Hematology & Oncology $281,918
Dr. Shahzad Raza, Md, MD
Hematology & Oncology — Payments: $184,113
Hematology & Oncology $184,113
Joseph Mcguirk, D.o, D.O
Hematology & Oncology — Payments: $129,700
Hematology & Oncology $129,700
Jaswinder Singh, Md, MD
Hematology & Oncology — Payments: $86,702
Hematology & Oncology $86,702
Dr. Tara Lin, Md, MD
Hematology & Oncology — Payments: $24,114
Hematology & Oncology $24,114
Maureen Sheehan, M.d, M.D
Hematology & Oncology — Payments: $18,955
Hematology & Oncology $18,955